INTRODUCTIONUterine carcinosarcoma (UCS) is a rare but aggressive type of high‐grade endometrial cancer, and represents a disease of epithelial‐mesenchymal transition with the sarcoma element arising and dedifferentiated from the carcinoma component. Aggressiveness of UCS is clinically reflected in its stage distribution of tumors: unlike low‐grade endometrial cancer where the majority of tumors present with early stage disease, nearly half of UCS cases are advanced‐stage, including more than 10% with stage IV disease.Regardless of cancer stage, the standard treatment approach for high‐grade endometrial cancer including UCS is primary surgery consisting of hysterectomy, bilateral salpingo‐oophorectomy, lymphadenectomy, and/or resection of metastatic tumor implants if present. However, while primary surgical treatment is generally preferred, patients with stage IV disease are often not suitable surgical candidates for various reasons. These include presence of extensive disease burden and distant parenchymal metastasis, poor performance status, or deconditioning, and extensive medical comorbidity. All of these factors reflect the unique characteristics of UCS; specifically, that UCS is more common in elderly women and often demonstrates wide‐spread tumor progression.Neoadjuvant chemotherapy is an alternative treatment approach for patients who are not suitable for primary surgical treatment. The role of neoadjuvant chemotherapy has been studied in various types of gynecologic malignancy
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera